AFFIMED NV (AFMD) Stock News

NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock - Currency: USD

0.1815 -0.1 (-34.95%)

After market: 0.1731 -0.01 (-4.63%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AFMD Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Zacks Investment Research - Mentions: CGEN

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

3 months ago - By: Benzinga - Mentions: PTIX HCTI ZIM FAAS ...

Dow Tumbles 200 Points; ZIM Integrated Shipping Services Posts Upbeat Earnings

3 months ago - By: Benzinga - Mentions: HCTI TSSI INZY ZENV ...

US Stocks Edge Higher; Consumer Sentiment Falls In May

3 months ago - By: Zacks Investment Research - Mentions: MRSN

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

3 months ago - By: Affimed N.V.

Affimed Announces Receipt of Nasdaq Delisting Notice

3 months ago - By: Affimed N.V.

Affimed Announces Receipt of Nasdaq Delisting Notice

3 months ago - By: Zacks Investment Research - Mentions: MGTX

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

3 months ago - By: Affimed N.V.

Affimed Announces Filing for the Opening of Insolvency Proceedings

3 months ago - By: Affimed N.V.

Affimed Announces Filing for the Opening of Insolvency Proceedings

3 months ago - By: Zacks Investment Research - Mentions: BTAI

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

4 months ago - By: Affimed N.V.

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

4 months ago - By: Affimed N.V.

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

4 months ago - By: Affimed N.V.

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

4 months ago - By: Affimed N.V.

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

4 months ago - By: Affimed N.V.

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

4 months ago - By: Affimed N.V.

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

5 months ago - By: Affimed N.V.

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

5 months ago - By: Affimed N.V.

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

5 months ago - By: Affimed N.V.

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

5 months ago - By: Affimed N.V.

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

8 months ago - By: Affimed N.V.

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

8 months ago - By: Affimed N.V.

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)